All Genomics & Sequencing articles – Page 5
-
NewsNew mRNA therapy targets drug-resistant pneumonia
A new mRNA therapy that prompts the body to produce bacteria-killing ‘peptibodies’ has shown early success in preclinical models, offering a potential new tool in the fight against antibiotic-resistant pneumonia.
-
ArticleMapping the genome in 3D to reveal new drug targets
Find out how a three-dimensional view of the genome is giving scientists a clearer picture of disease biology and revealing new opportunities for targeted therapies.
-
NewsOTULIN enzyme found to control tau production in Alzheimer’s
New research has shown that the enzyme OTULIN regulates tau at the gene-expression level rather than through protein degradation.
-
ArticleMapping lipid pockets to drug the undruggable proteome
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
-
NewsBlood stem cell and islet cell transplant combo reverses Type 1 diabetes
Stanford researchers have cured Type 1 diabetes in mice using a combination of blood stem cell and pancreatic islet cell transplants.
-
ArticleAdvancing disease biomarker research with EV multiplex profiling
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
-
NewsBacterial traces discovered within gliomas and brain metastases
Scientists have discovered active bacterial traces inside brain tumours, overturning assumptions about the brain’s sterility and opening up new possibilities for understanding – and potentially treating – gliomas and brain metastases.
-
ArticleRVX-001: a universal vaccine to tackle antimicrobial resistance
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
-
ArticleDeep data not big data
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
-
ArticleAI and the future of biomarker analysis in early R&D
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
-
ArticleWhy first-void urine could potentially change the future of HPV screening
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
-
ArticleBeyond weight loss: the gap in current drug development for obesity
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
-
NewsAlzheimer’s may disrupt fat tissue and raise metabolic disease risk
Researchers have discovered that Alzheimer’s may disrupt communication between nerves and blood vessels in fat tissue which could explain why people with Alzheimer’s are often diagnosed with heart disease and metabolic problems.
-
ArticleInside ELRIG Drug Discovery 2025: automation, AI and human-relevant models
At ELRIG’s Drug Discovery 2025, Drug Target Review spoke with the teams turning big ideas into usable tools – automation, AI and biology – that help scientists work smarter.
-
ReportLab Automation: Where Discovery Scales
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
-
NewsTRF1 protein identified as potential obesity drug target
Researchers have discovered that removing a telomere-protecting protein, TRF1, makes mice leaner and metabolically healthier without shortening their telomeres, potentially leading to new methods for tackling obesity and age-related diseases.
-
NewsHow AI and cell data combine to make drug discovery faster
Cellarity has published a new paper in detailing an AI-powered framework that integrates single-cell transcriptomics to make drug discovery faster and more successful.
-
ArticleFrom wild fungi to faster drug discovery
Nature’s pharmacy has yielded half of today’s medicines, yet most of its potential remains untapped. AI is now changing how quickly new therapies can be found.
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part II
Part II shows that the predictive validity crisis can be solved by rethinking how the industry chooses models, measures outcomes and integrates systems. Success stories from Vertex, Regeneron and AstraZeneca illustrate how aligning biology, measurement and strategy can reverse decades of declining productivity.
-
NewsNew compound blend reverses sugar damage to tackle ageing and obesity
Scientists have developed a compound blend that reverses sugar-related cellular damage in mice, which could lead to future therapies to slow ageing and treat metabolic diseases.


